Recombinant Human Keratinocyte Growth Factor Ameliorates Cancer Treatment‐Induced Oral Mucositis on a Chip

Abstract

AbstractOral mucositis (OM) is a severe complication of cancer therapies caused by off‐target cytotoxicity. Palifermin, which is recombinant human keratinocyte growth factor (KGF), is currently the only mitigating treatment available to a subset of OM patients. This study used a previously established model of oral mucositis on a chip (OM‐OC) comprised of a confluent human gingival keratinocytes (GIE) layer attached to a basement membrane‐lined subepithelial layer consisting of human gingival fibroblasts (HGF) and human dermal microvascular endothelial cells (HMEC) on a stable collagen I gel. Cisplatin, radiation, and combined treatments are followed by a recovery period in the OM‐OC to determine possible cellular and molecular mechanisms of OM under effects of KGF. Cancer treatments affected the keratinocyte layer, causing death and epithelial barrier loss. Both keratinocytes and subepithelial cells died rapidly, as evidenced by propidium iodide staining. In response to radiation exposure, cell death occurred in the apical epithelial layer, predominantly, within 24h. Cisplatin exposure predominantly promoted death of basal epithelial cells within 32‐36h. Presence of KGF in OM‐OC protected tissues from damage caused by cancer treatments in a dose‐dependent manner, being more effective at 10 ng/mL. As verified by F‐actin staining and the Alamar Blue assay, KGF contributed to epithelial survival and induced proliferation of GIE and HGF as well as HMEC within 120h. When the expression of eighty inflammatory cytokines is evaluated at OM induction (Day 12) and resolution (Day 18) stages in OM‐OC, some cytokines are identified as potential novel therapeutic targets. In comparison with chemoradiation exposure, KGF treatment showed a trend to decrease IL‐8 and TNF‐a expression at Day 12 and 18, and TGF‐β1 at Day 18 in OM‐OC. Taken together, these findings support the utility of OM‐OC as a platform to model epithelial damage and evaluate molecular mechanisms following OM treatment.